Dianthus Therapeutics, Inc. (DNTH) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Dianthus Therapeutics (DNTH) relies on an independent product cycle, which establishes it as a defensive asset during recessions. Its scientific potential is based on the development of monoclonal antibodies for the therapy of autoimmune pathologies. This EV/EBITDA chart helps identify shifts in cycle phases, while 0.00 characterizes this valuation parameter. The strategy focuses on the release of convenient subcutaneous complement system inhibitors.
dianthustx.com - analytical breakdowns and key metrics (DNTH)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Dianthus Therapeutics|DNTH - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Dianthus Therapeutics, Inc.|DNTH - Company Cumulative Debt|Debts to Book Capitalization Dianthus Corp|DNTH - Company Long-Term Indebtedness|Company Short-Term Debts Dianthus Therapeutics|Quick Ratio dianthustx.com
- business earnings and investment ratios data:
DNTH - Net Profit|Expected Profit Dianthus Therapeutics|DNTH - Price to Earnings Multiple|Projected Price to Earnings Dianthus Therapeutics|DNTH - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Dianthus Corp|DNTH - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Dianthus Therapeutics|DNTH - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months dianthustx.com|DNTH - Expected net earnings per share growth this year|Expected earnings per share growth for next year Dianthus Therapeutics
Initial company analysis:Dianthus Pharma DNTH
Developing targeted complement inhibitors for the treatment of autoimmune pathologies requires significant capital expenditures, making business valuation through the lens of debt load critically important. By analyzing changes in the EV/EBITDA ratio of Dianthus Therapeutics (DNTH), an investor compares the total enterprise value with its operating profit before taxes and amortization, identifying discrepancies between the market price and the actual ability of the assets to generate cash flow.
Competitor analysis for Dianthus Therapeutics
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|Vera Pharma - EV/EBITDA Multiple|PHVS (Pharvaris Pharma) - Enterprise Value to Operating Income Before Depreciation|ABCL: EV/EBITDA Multiple|TRML - Total Company Value to Operating Income Before Depreciation Ratio|PGEN (Precigen) - EV/EBITDA Multiple|EV/EBITDA Multiple Pharming Group NV|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nektar (NKTR)|Upstream Pharma - Enterprise Value to Operating Income Before Depreciation|Zenas Biopharma Inc - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio IMNM (immunome.com)|Gossamer Bio - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation KALV (KalVista Pharma)|SEPN (Septerna Corp) - Enterprise Value to EBITDA Ratio|Pieris Corp (PVLA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Savara Inc.|rigel.com (RIGL) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio ANAB (AnaptysBio)|ATXS (Astria Therapeutics Inc) - Business Value to Operating Income Before Depreciation|enGene Bio - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio RAPT (rapt.com)|Aerovate - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ACRS (aclaristx.com)|KYTX: EV/EBITDA Multiple|Company Value to EBITDA Tiziana Life Sciences Ltd. (TLSA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cabaletta Bio, Inc|VTYX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple THTX|EV/EBITDA Multiple avalotx.com (AVTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eledon Pharmaceuticals, Inc. ELDN|AGEN (Agenus, Inc.) - Company Value to Operating Income Before Depreciation Ratio|Climb Bio, Inc. - EV/EBITDA Multiple|Company Value to EBITDA zurabio.com|ATYR (aTyr Pharma, Inc.) - Enterprise Value to EBITDA Ratio|Adagene Inc. (ADAG) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio IMA|STTK (Shattuck Therapeutics) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple EQ|Total Company Value to Operating Income Before Depreciation Ratio connectbiopharm.com|EV/EBITDA Multiple IMUX (Immunic)|ATRA - Enterprise Value to EBITDA Ratio|IFRX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio X4 Pharmaceuticals Inc. XFOR|ACET: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation CELU|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INmune Bio, Inc.|Enterprise Value to Operating Income Before Depreciation BRNS (barinthusbio.com)|Enterprise Value to EBITDA Ratio KZR (Kezar Life Sciences, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio SABS|EV/EBITDA Multiple AKTX (Akari Therapeutics plc)|Business Value to Operating Income Before Depreciation ENLV|QTTB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio GOVX|EDSA: EV/EBITDA Multiple|iBio Inc - Business Value to Operating Income Before Depreciation|CARM (Carisma Therapeutics Inc) - EV/EBITDA Multiple|EV/EBITDA Multiple XTL Bio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bolt Biotherapeutics (BOLT)|HCWB (hcwbiologics.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aptevo Therapeutics Inc. APVO|AIM - Enterprise Value to EBITDA Ratio|Aditxt Corp - EV/EBITDA Multiple|GRI - EV/EBITDA Multiple|XRTX (XORTX Therapeutics Inc.) - Enterprise Value to EBITDA Ratio|reshapelifesciences.com - Business Value to Operating Income Before Depreciation|REVB (Revelation Biosciences, Inc.) - EV/EBITDA Multiple|Indaptus Therapeutics Inc (INDP) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Scinai (SCNI)|Enterprise Value to EBITDA Ratio calcimedica.com CALI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK - Enterprise Value to EBITDA Ratio|HOOK: Enterprise Value to EBITDA Ratio|IGMS - EV/EBITDA Multiple|iTeos (ITOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation OCEA|TCBP (TC Biopharm) - EV/EBITDA Multiple|Company Value to EBITDA thirdharmonicbio.com THRD
